AEON Biopharma, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
AEON Biopharma received written notice from NYSE American on August 3, 2026, confirming it regained compliance with continued listing standards relating to stockholders' equity (Sections 1003(a)(i) and 1003(a)(ii)). The company closed an underwritten public offering on July 15, 2026, raising $13.6M net proceeds from 17.9M shares of common stock and 24.8M pre-funded warrants, with an additional 4.7M shares sold via over-allotment on July 23. The offering included milestone warrants with potential for up to $34.0M in additional gross proceeds, bringing stockholders' equity above the $4.0M minimum requirement; the .BC delisting indicator will be removed from the trading symbol.
Why this rating
Delisting prevention is survival-critical for $8.7M-market-cap company; $13.6M raise is 156% of market cap, materially extending runway and resolving existential compliance threat.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.